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http:WHAT THIS PAPER ADDS
The use of beta-blockers has been considered controversial in patients with peripheral arterial disease (PAD).
However, our data provide evidence that beta-blocker treatment is safe and effective in unselected symptomatic
PAD patients in routine clinical settings. To our knowledge, the inﬂuence of beta-blocker use on the rate of major
amputation has not been described previously.
We hope that our results will contribute to the continuous improvement in the use of secondary medical
prevention and thereby reduce the burden of cardiovascular events for this high-risk population.Objective: To explore the associations between beta-blocker use and clinical outcomes (death, hospitalisation
with myocardial infarction (MI) or stroke, major amputation and recurrent vascular surgery) after primary
vascular reconstruction.
Methods: Patients who had primary vascular surgical or endovascular reconstruction due to symptomatic
peripheral arterial disease, in Denmark between 1996 and 2007 were included. We obtained data on ﬁlled
prescriptions, clinical outcomes and confounding factors from population-based healthcare registries. Beta-
blocker users were matched to non-users by propensity score, and Cox-regression was performed. All
medications were included as time-dependent variables.
Results: We studied 16,945 matched patients (7828 beta-blocker users and 9117 non-users) with a median
follow-up period of 582 days (range, 30e4379 days). The cumulative risks were as follows: all-cause mortality,
17.9%; MI, 5.3%; stroke, 5.6%; major amputation, 9.1%; and recurrent vascular surgery, 23.1%. When comparing
beta-blocker users with non-users: adjusted hazard ratio: MI, 1.52 (95% CI, 1.31e1.78); stroke, 1.21 (95% CI,
1.03e1.43); and major amputation, 0.80 (95% CI, 0.70e0.93).
Conclusion: Beta-blocker use after primary vascular surgery was associated with a lower risk of major amputation
but an increased risk of hospitalisation with MI and stroke. No associations were found between beta-blocker use
and all-cause mortality or the risk of recurrent vascular surgery. However, our results are not sufﬁcient to alter
the indication for beta-blocker use among symptomatic peripheral arterial disease patients.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Peripheral arterial disease (PAD) is a common manifestation
of systemic atherosclerosis and is associated with a signiﬁ-
cant cumulative risk of cardiovascular events, including
death, myocardial infarction (MI), stroke and major ampu-
tation.1e5 The prevalence of hypertension among PAD pa-
tients is higher than in the general population, and bloodrresponding author. A. Høgh, Department of Vascular Surgery, Car-
ular Research Unit, Heibergs Alle 4, 8800 Viborg, Viborg Regional
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//dx.doi.org/10.1016/j.ejvs.2013.04.006pressure control is considered critical for secondary medical
prevention in patients with PAD; however, the use of sec-
ondary medical prevention is generally insufﬁcient for PAD
patients2,6e10 when compared with clinical guidelines and
recommendations.11e15
Beta-adrenoceptor blocking agents (beta-blockers) are
traditionally used to treat hypertension and are the primary
treatment choice after MI or for chronic angina.16,17 How-
ever, beta-blocker treatment has been considered contro-
versial in PAD patients because it is suspected that beta-
blockers cause a-receptor-mediated peripheral vasocon-
striction and reduced peripheral circulation, leading to
intermittent claudication symptoms. Two meta-analyses
disproved this hypothesis and concluded that beta-
blockers are safe in PAD patients and do not affect
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dication.18e20 However, there are few data on the safety
and efﬁcacy of beta-blocker treatment among unselected
symptomatic PAD patients in routine clinical settings.
The primary objective of this study was to examine
clinical outcomes following beta-blocker treatment after
primary vascular reconstruction in unselected symptomatic
PAD patients in a population-based, long-term follow-up
study.
PATIENTS AND METHODS
This study was based on data from nationwide Danish
population-based healthcare and administrative databases.
The linking of individual records across the registries is
possible using civil registration numbers, which are unique
10-digit personal identiﬁcation numbers given to all citizens
(the Danish population consists of approximately 5.5 million
people) and used in all Danish registries.21 The Danish Na-
tional Health Service provides tax-supported healthcare
with free access to hospital care, surgery, general practi-
tioners and reimbursement for many prescribed
medications.
Study population
We included all patients who had primary vascular surgical
or endovascular reconstruction due to atherosclerotic dis-
ease between 1997 and 2007. The indications for surgery
included moderate intermittent claudication, ischaemic rest
pain, ulceration and gangrene. The patients were identiﬁed
using the Danish Vascular Registry, which is a national
clinical registry that has been used for prospective data
collection since 1996 with mandatory reporting for all
Danish vascular surgery departments (n ¼ 9). The primary
objectives of the registry are surveillance and quality
improvement. The registry contains 65 variables, including
indication for surgery, timing of surgery (acute/elective),
patient characteristics, smoking habits, type of intervention,
vascular patency at discharge and discharge destination.22
Patients were only included for their ﬁrst vascular proce-
dure during the study period. Patients who died within 30
days of discharge and patients less than 40 years old were
excluded (Fig. 1).
We validated the Danish Vascular Registry by comparing
it with a national random sample of 200 medical records
and found discrepancies of less than 1% for operation-
related data and vascular patency at discharge. Addition-
ally, we found discrepancies of less than 3% for the type of
surgery.
Prescription information
We identiﬁed the prescriptions ﬁlled by the included pa-
tients throughout the follow-up period (1997e2007); pre-
scriptions were for antihypertensive drugs (beta-blockers,
angiotensin-converting enzyme inhibitors, angiotensin II
receptor antagonists, calcium antagonists and diuretics),
antiplatelet drugs (low-dose aspirin, dipyridamole and clo-
pidogrel) and lipid-lowering drugs. The data were obtainedfrom the Medical Register of the Danish Medicines Agency
and identiﬁed on the basis of Anatomical Therapeutical
Chemical (ATC) classiﬁcation system. In Denmark, secondary
medical prevention is only available by prescription with the
exception of low-dose aspirin; however, regular aspirin is
available by prescription and reimbursed for pensioners and
patients with chronic diseases.Clinical outcomes
Five competing end points were assessed: major amputa-
tion, hospitalisation with MI or stroke, recurrent vascular
surgery and all-cause mortality. Data from hospitalisations
(MI, stroke and/or major amputation) were obtained from
the Danish National Patient Register, which contains infor-
mation on all discharges from Danish hospitals since 1977,
including the date and the diagnosis at discharge encoded
according to the International Classiﬁcation of Diseases (8th
revision until 1993 and 10th revision thereafter).23 Data on
recurrent vascular surgery were obtained from the Danish
Vascular Registry as described earlier. Information on mor-
tality during follow-up was obtained from the Danish Civil
Registration System, which has maintained birth and death
records for the entire population since 1968.21Covariates
A complete hospitalisation history until the primary oper-
ation date was compiled for each patient based on data
from the Danish National Patient Register. Additionally, a
comorbidity index score based on the methods of Charlson
et al.24 was computed for each patient. Three levels of co-
morbidity were deﬁned: no comorbidity (score 0), low co-
morbidity (score 1e2) and high comorbidity (score > 2).
The comorbidity index has previously been adapted and
validated for use in the analysis of hospital discharge reg-
istry data.25 Information on socio-economic status was ob-
tained from the Integrated Database for Labour Market
Research, which is updated yearly. We classiﬁed patients
according to marital status (single, married, widowed or
divorced), employment status (employed, pensioner or
other), gross income in quartiles and educational level
(primary and lower secondary school, upper secondary
school, vocational education and higher education). The
Danish Vascular Register provided information on the
following clinical and operative variables: acute or elective
surgery, region of surgery (central [abdominal aortic seg-
ments and iliac vessels], groin or peripheral arteries),
vascular patency at discharge, discharge destination and
smoking habits at the time of surgery.Statistics
Patient characteristics were compared using a two-sample
test of proportions. A p value < .05 was considered sta-
tistically signiﬁcant. Because beta-blocker use was not
randomly assigned in the study population, we used the
calliper method of propensity score matching with a .2
standard deviation of the logit of the estimated propensity
Figure 1. Flow diagram of the study population.
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bias.26,27
Beta-blocker users were deﬁned as those having ﬁlled at
least one prescription 180 days before or after primary
vascular reconstruction. Up to ﬁve non-users were matched
to each beta-blocker user. Beta-blocker users not matched
to a non-user were excluded (Fig. 1). Users were matched
based on the following covariates: gender, age group, co-
morbidity index, hospital history, operation type, marital
status, employment, education level, gross income in
quartiles, tobacco use, acute operation, patency at
discharge and discharge destination. An absolute stand-
ardised difference of <10% and a variance ratio between
0.8 and 1.25 were considered to support the assumption of
balance between the groups28,29 (Figs. 2 and 3).
Cox regression analysis and the estimation of adjusted
hazard ratios (adj. HRs) were performed after matching,
which enabled us to adjust for potential residual con-
founders using non-users as references. The Cox regression
analyses were conducted using a multivariant model basedon competing risk analysis of the end points (all-cause
mortality, MI, stroke, major amputation and/or recurrent
vascular surgery) with an adjustment for baseline covariates
and medications used during the follow-up period (angio-
tensin II receptor antagonists, angiotensin-converting
enzyme inhibitors, calcium antagonists, diuretics, anti-
platelet drugs and lipid-lowering drugs).
We evaluated the robustness of our results by
repeating the analyses after stratifying for previous MIs
because the full balance between beta-blocker users and
non-users was not achieved despite propensity score
matching. Furthermore, we repeated the analyses using
the entire study population, including the propensity
score for beta-blocker use as a covariate after trans-
forming it into cubic splines, which describe a continuous
smooth function and provide a general and robust
approach for adapting linear methods to the modelling of
non-linear relationships.
All data analyses were performed using STATA version
11.2 (Statacorp) and SAS 9.2 (Rx64 2.13.0).
Figure 2. The standardised differences in variables included in the propensity score for the entire study population (B) and for the
propensity score-matched patients (C).
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Patient characteristics
Table 1 displays the characteristics of the study population
according to beta-blocker usebefore andafter propensity score
matching. Beta-blocker users had a signiﬁcantly higher risk of
being admitted with a MI (16.4% vs. 5.4%) or stroke (12.2% vs.9.2%) prior to primary vascular reconstruction. In contrast, we
found no major differences in gender, operation type (central
(abdominal aortic segments and iliac vessels), groin or pe-
ripheral arteries), indication for operation (acute, intermittent
claudication, rest pain or tissue loss) or socio-economic vari-
ables between the two groups. The proportions of percuta-
neous transluminal angioplasty in the iliac system increased
Figure 3. The variance ratios of variables, including the propensity score for the entire study population (B) and for the propensity score-
matched patients (C).
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the early period (1996e2000) to 30.9% in the late period
(2001e7). A signiﬁcantly lower proportion of current smokers
were beta-blocker users (56.3% vs. 44.8%). After propensity
score matching, an acceptable balance was achieved for all
examined covariates with the exception of MI (Figs. 2 and 3).Beta-blocker use and clinical outcomes
Patients were followed for a median of 582 days (range,
30e4379 days). Table 2 displays the absolute risk of the
competing outcomes and the corresponding adjusted HRs
with 95% CI; for the matched population, we used the non-
users as a reference group.
Table 1. Descriptive characteristics.
Before propensity score matching (n ¼ 18,527) After propensity score matching (n ¼ 16,945)
þBeta-blockers Beta-blockers p-Value þBeta-blockers Beta-blockers p-Value
(n ¼ 8357) (n ¼ 1,0170) (n ¼ 7828) (n ¼ 9117)
Male 53.5 53.5% .05 52.9% 54.3% .18
Age group
40e60 years 20.7 23.8 .02 20.1 22.1 .14
60e80 years 65.4 61.7 <.01 65.9 63.5 .01
> 80 years 13.9 14.6 .63 14.1 14.4 .93
Comorbidity index
None (0) 27.1 32.3 <.01 26.9 30.8 <.01
Low (1e2) 51.1 50.4 .48 51.4 51.1 .77
High (>2) 21.8 17.4 <.01 21.7 18.1 .01
Medical history
Myocardial infarction 16.4 5.4 <.01 15.1 6.0 <.01
Stroke 12.2 9.2 .04 12.3 9.8 .09
COPD 6.5 8.3 .20 6.2 7.5 .40
Diabetes 14.6 12.0 <.01 14.6 12.0 <.01
Socioeconomic status
Marital status
Married 55.0 51.0 <.01 55.1 52.3 .07
Divorced 14.5 16.2 .20 14.2 15.5 .22
Unmarried 5.9 7.9 .18 5.8 7.3 .04
Widowed 24.7 24.9 .86 24.9 24.9 1.00
Employment
Employed 16.6 19.5 .033 16.2 18.4 .12
Pensioner 79.9 76.3 <.01 80.4 77.7 <.01
Other 3.5 4.2 .63 3.4 3.9 .74
Education level
No information 11.5 15.5 <.01 11.2 13.5 .12
Primary and lower
sec. school
49.6 47.0 .14 49.8 48.3 .17
Upper secondary
school and vocational education
30.8 30.0 .53 30.7 30.4 .71
Higher education 8.2 7.6 .65 8.3 8.0 .75
Clinical data
Operation type
Abdominal aortic segments
and iliac arteries
35.2 35.7 .66 35.3 36.0 .53
Groin arteries 36.4 34.4 .10 36.7 35.6 .36
Peripheral arteries 28.5 29.9 .26 28.1 28.4 .80
Indication
Acute 10.9 11.0 .95 11.0 11.4 .79
Intermittent claudication 37.4 39.0 .17 37.5 39.1 .19
Rest pain 16.2 16.9 .63 16.2 16.6 .78
Tissue loss 24.1 25.0 .49 24.0 24.5 .65
Other 11.4 8.2 .02 11.3 8.3 .04
Tobacco use
Non-smoker 18.5 13.4 <.01 18.7 14.7 <.01
Former smoker 29.7 24.3 <.01 30.5 26.4 <.01
Current smoker 44.8 56.3 <.01 43.7 52.4 <.01
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Table 1-continued
Before propensity score matching (n ¼ 18,527) After propensity score matching (n ¼ 16,945)
þBeta-blockers Beta-blockers p-Value þBeta-blockers Beta-blockers p-Value
(n ¼ 8357) (n ¼ 1,0170) (n ¼ 7828) (n ¼ 9117)
No information 7.0 6.0 .48 7.1 6.5 .65
Patency at discharge
Closed 2.6 3.2 .96 2.6 3.1 .76
Open 91.1 91.8 .13 91.1 91.4 .77
No reconstruction 4.6 3.6 .48 4.6 3.9 .68
No information 1.7 1.4 .88 1.7 1.6 .93
Discharged to
Home 80.5 79.2 .05 80.3 79.2 .13
Nursing home 17.2 18.2 .50 17.4 18.1 .62
Hospital 2.3 2.7 .79 2.3 2.6 .83
No information 0.1 0.1 .00 0.1 0.1 1.00
COPD ¼ chronic obstructive pulmonary disease. Data are presented as percentages.
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no signiﬁcant association was found between beta-blocker
use and all-cause mortality (adj. HR, 0.92; 95% CI, 0.84e
1.02). In contrast, we found signiﬁcant associations be-
tween beta-blocker use and the risk of MI or stroke. The adj.
HRs were 1.52 (95% CI, 1.31e1.78) and 1.21 (95% CI, 1.03e
1.43) for MI and stroke, respectively. The cumulative risk of
major amputation was 9.1%, and beta-blocker use was
associated with a signiﬁcant risk reduction in this outcome
(adj. HR 0.80; 95% CI, 0.70e0.93). Moreover, 23.1% of the
population had recurrent vascular reconstruction, but no
signiﬁcant association with beta-blocker use was found (adj.
HR, 0.99; 95% CI, 0.91e1.07).
After stratiﬁcation according to prior MI and stroke, we
repeated the analyses in the propensity-matched popula-
tion (Table 3). After stratiﬁcation by MI, the overall cumu-
lative risk of major amputation was unchanged; however,
after the adjustment, we found a stronger association be-
tween beta blocker use in patients without a prior MI and
decreased rates of major amputation (adj. HR, 0.77; 95% CI,
0.66e0.90). No difference was seen among beta-blocker
users with a prior MI (adj. HR, 1.05; 95% CI, 0.72e1.53).
The cumulative risk of MI during the follow-up period
was twice as high among patients with a prior MI as inTable 2. Adjusted hazard ratios with 95% CIs for competing advers
population (n ¼ 18,527) and propensity score-matched population
reference group.
Entire study population
Events (%) Adjusted HRa
All-cause mortality 18.2 0.95 [0.86;1.0
MI 5.3 1.38 [1.18;1.6
Stroke 5.5 1.16 [0.98;1.3
Major amputation 9.1 0.83 [0.72;0.9
Recurrent vascular surgery 23.3 1.00 [0.86;1.0
a Adjusted for age, Charlson’s comorbidity index, socioeconomic statu
smoking, acute/non-acute surgery, operation type, indication for ope
during follow-up (angiotensin-converting enzyme/angiotensin II recepto
lipid-lowering drugs).patients without a prior MI (4.6% vs. 11.3%). However, after
the adjustment, we found an increased risk of MI among
beta-blocker users without a prior MI (adj. HR, 1.58; 95% CI,
1.32e1.89). No differences were seen among beta-blocker
users with a previous MI (adj. HR, 1.10; 95% CI, 0.80e
1.52). Additionally, beta-blocker users with a previous MI
were at increased risk of having a stroke (adj. HR, 1.63; 95%
CI, 1.09e2.44), while beta-blocker users without a previous
MI had an unchanged risk. Beta-blocker users with a prior
stroke had a decreased cumulative risk of having a recurrent
stroke compared with beta-blocker users without a prior
stroke but an increased adj. HR compared with non-users
(Table 3).
The use of other antihypertensive agents (angiotensin II
receptor antagonists, angiotensin-converting enzyme in-
hibitors, calcium antagonists, diuretics, antiplatelet drugs
and lipid-lowering drugs) during the follow-up period has
previously been described.30DISCUSSION
In this nationwide follow-up study of all patients undergo-
ing primary vascular reconstruction in Denmark over a 10-
year period, we found that beta-blocker use wase clinical outcomes according to beta-blocker use in the entire
(n ¼ 16,945). Patients not using beta-blockers serve as the
Propensity score-matched population
(95% CI) Events (%) Adjusted HRa (95% CI)
5] 17.9 0.92 [0.84;1.02]
0] 5.3 1.52 [1.31;1.78]
7] 5.6 1.21 [1.03;1.43]
5] 9.2 0.80 [0.70;0.93]
5] 23.1 0.99 [0.91;1.07]
s (gross income, education level, marital status and employment),
ration discharge destination, patency at discharge, and drug use
r antagonists, calcium antagonists, diuretics, antiplatelet drugs and
Table 3. Adjusted hazard ratios with 95% CIs for competing adverse clinical outcomes according to beta-blocker use in the propensity
score-matched population (n ¼ 16,945) stratiﬁed to prior myocardial infarction (MI) or stroke.
All-cause mortality MI Stroke Major amputation Recurrent vascular
surgery
MIa,b (%) (n ¼ 12,518)
Adj. HR (95% CI)
17.5
0.92 [0.82;1.02]
4.6
1.58 [1.32;1.89]
5.3
1.15 [0.95;1.38]
9.3
0.77 [0.66;0.90]
23.5
1.00 [0.91;1.10]
þMIa,b (%) (n ¼ 1727)
Adj. HR (95% CI)
21.1
0.79 [0.75;1.24]
11.3
1.10 [0.80;1.52]
7.1
1.63 [1.09;2.44]
8.9
1.05 [0.72;1.53]
20.2
1.02 [0.80;1.29]
Strokea,b (%)
(n ¼ 15,087)
Adj. HR (95% CI)
17.6
0.93 [0.84;1.04]
5.1
1.59 [1.35;1.89]
5.1
1.25 [1.04;1.50]
8.8
0.80 [0.68;0.93]
26.2
1.02 [0.94;1.12]
þStrokea,b (%)
(n ¼ 1858)
Adj. HR (95% CI)
19.9
0.89 [0.67;1.18]
6.5
1.13 [0.74;1.73]
8.6
1.00 [0.68;1.49]
12.3
0.90 [0.63;1.28]
22.8
0.77 [0.60;0.99]
a Adjusted for age, Charlson’s comorbidity index, socioeconomic status (gross income, education level, marital status and employment),
smoking, acute/non-acute surgery, operation type, indication for operation discharge destination, patency at discharge, and drug use
during follow-up (angiotensin-converting enzyme/angiotensin II receptor antagonists, calcium antagonists, diuretics, antiplatelet drugs and
lipid-lowering drugs).
b Patients not using beta-blockers serve as the reference group.
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amputation compared with the risk in non-users. European
Society of Cardiology guidelines for 2011 state that beta-
blockers are not contraindicated in PAD patients11 based
on previous reports concluding beta-blockers are safe in
PAD patients despite their suspected negative effects on
walking capacity and impairment of intermittent claudica-
tion18e20 Our ﬁndings regarding the reduced risk of future
major amputation support these reports, although, to our
knowledge, the inﬂuence of beta-blocker use on the
amputation rate has not been previously described.
Our ﬁnding that beta-blockers are associated with an
increased risk of MI and/or stroke during the follow-up
period is not in accordance with ﬁndings of previous
studies, including those on symptomatic PAD patients with
prior MI, that found beta-blocker use to be associated with
a lower risk of MI.31,32 These conﬂicting data might reﬂect
residual confounding effects despite our attempt to mini-
mise bias and confounding effects through statistical
adjustment and study design. However, it should be noted
that a recent systematic review reported that high-dose
beta-blockers increased systolic blood pressure variability,
a powerful risk factor for stroke.33
Randomised clinical trials have found that beta-blocker
use following MI in symptomatic PAD patients is associ-
ated with a signiﬁcant reduction in early and late mortal-
ity.34,35 However, we were unable to conﬁrm this ﬁnding in
our study, which is likely an indicator of residual or unac-
counted confounding variables.
Beta-blockers are effective antihypertensive agents and
are prescribed for their cardiovascular effects, including the
prevention of the disruption of vulnerable atherosclerotic
plaques by reducing heart rate and blood pressure;36
however, adverse effects and possible consequences of
beta-blocker use in PAD patients have been described,
including the undesirable change in cholesterol
metabolism37e41 due to the decrease in high-density
lipoprotein concentrations and the increase in triglyceride
concentrations. The long-term impacts of these effects areunknown but could theoretically increase the progression of
PAD symptoms because of arterial occlusion impairment.
Another disadvantage of beta-blockers is their lack of in-
ﬂuence on arterial structure or function in contrast to
angiotensin II antagonists.42Strengths and limitations
The major strengths of our study include the population-
based design; the availability of detailed, prospectively
collected, individual-level data; and complete follow-up. To
minimise the risk of confounding bias, we used propensity
score matching and a multivariable model based on
adjusted competing risk analysis. This two-step procedure
makes the model-based inferences less model- dependent
and more accurate.27
However, selection bias may be present because beta-
blockers were not the drug of choice for hypertension in
symptomatic PAD patients for the majority of the studied
period. During the entire study period, an average of 45% of
the patients in our study population were taking beta-
blockers. Furthermore, confounding could arise from the
lack of information on the contraindications for beta-
blocker use in individual patients, including chronic
obstructive pulmonary disease, atrioventricular block, se-
vere congestive heart failure, hypotension, bradycardia and
gangrene.18,43 These contraindications occur frequently and
may be associated with adverse clinical outcomes. For
example, a previous study described adverse effects that
caused the discontinuation of initiated beta-blocker use in
12% of patients with prior MI and symptomatic PAD.31
Additionally, we used prescriptions ﬁlled by the patients
as a proxy for actual drug use, but we had no information
regarding patient compliance. However, mandatory self-
payment indicates that a purchased prescription is likely
to reﬂect actual medication use.
Finally, our estimates depend on the accuracy of the data
sources. The accuracy of the Danish Vascular Registry was
previously described as good;22 our study further conﬁrmed
A. Høgh et al. 101this classiﬁcation (see Patients and methods). Furthermore,
the Danish Patients Registry has high validity for many di-
agnoses including MI, cancer and diabetes.44
CONCLUSION
In a study population of patients who had primary vascular
reconstruction surgery between 1996 and 2007, beta-
blocker use was associated with a decrease in the risk of
major amputation compared with the risk in non-users but
an increase in the risk of recurrent MI and/or stroke.
However, our results are not sufﬁcient to alter the indica-
tion of beta-blocker use among symptomatic PAD patients.
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